Maxalt
Product Images NDC 16590-461

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Maxalt (NDC 16590-461). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of Structural Formula (580e55c2 F9b7 4212 98b7 Cee54f55d309 01)

Chemical structure diagram of MAXALT active ingredient, showing a molecular structure with several nitrogen-containing rings and a carboxyl group. The structure includes a substituted indole and phenyl ring connected by various linkages.*

FDA Label Image

Image Of Figure 1 (580e55c2 F9b7 4212 98b7 Cee54f55d309 02)

A Kaplan-Meier plot illustrating the estimated probability of obtaining a headache response over 2 hours post-dose. The graph compares response rates for Placebo, MAXALT 5 mg, and MAXALT 10 mg, showing increasing effectiveness of MAXALT doses compared to placebo over time.*

FDA Label Image

Image Of Figure 2 (580e55c2 F9b7 4212 98b7 Cee54f55d309 03)

A Kaplan-Meier plot showing the estimated probability of remediation or rescue over 24 hours post-dose for MAXALT 5 mg, MAXALT 10 mg, and placebo. The graph depicts results from 4 placebo-controlled outpatient clinical trials measuring headache response and subsequent remediation within 24 hours.*

FDA Label Image

Image Of Figure 3 (580e55c2 F9b7 4212 98b7 Cee54f55d309 04)

A Kaplan-Meier plot illustrating the estimated probability of headache response over time up to 2 hours post-dose for three groups: placebo, MAXALT-MLT 5 mg, and MAXALT-MLT 10 mg. The graph compares headache response rates in a pooled analysis from two placebo-controlled, outpatient trials.*

FDA Label Image

Image Of Figure 4 (580e55c2 F9b7 4212 98b7 Cee54f55d309 05)

A Kaplan-Meier plot displaying the estimated probability of headache relief over 24 hours post-dose for MAXALT-MLT 5 mg, MAXALT-MLT 10 mg, and placebo groups. The x-axis shows hours post-dose, and the y-axis shows the estimated probability of headache relief, with the MAXALT doses showing higher probabilities than placebo throughout the 24-hour period.*

FDA Label Image

Label Image 10mg (Maxalt 10mg Label 461)

MAXALT 10 mg tablet blister pack label by STAT RX USA LLC and manufactured by Merck & Co., Inc. The label states the product contains 18 tablets with each tablet containing 14.53 mg of Rizatriptan Benzoate equivalent to 10 mg Rizatriptan. The label includes the NDC code 16590-461-18, storage instructions, and warning to keep out of reach of children.*

FDA Label Image

Label Image (Maxalt mLt 5mg 144)

MAXALT-MLT 5mg oral tablets label showing a package of 12 tablets by STAT RX USA LLC. Contains generic risatriptan with 14.53mg per tablet delivering 5mg of risatriptan active. Includes NDC 16590-144-12, manufacturer Merck & Co., and packaging details. The label includes warnings to keep out of reach of children and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.